Tocilizumab treatment in critical COVID-19: Report from a hospital center [Brief]

• Autores: Hueda-Zavaleta, Miguel, Bardales-Silva, Fabrizzio, Copaja-Corzo, Cesar, Flores-Palacios, Rodrigo, Barreto-Rocchetti, Luis, Córdova Tejada, Eyner
• Formato: artículo
• Fecha de Publicación: 2021
• Institución: Colegio Médico del Perú
• Repositorio: Acta Médica Peruana
• Lenguaje: español
• OAI Identifier: oai:ojs.pkp.sfu.ca:article/1919
• Enlace del recurso: https://amp.cmp.org.pe/index.php/AMP/article/view/1919
• Nivel de acceso: acceso abierto
• Materia: COVID-19; Respiratory Distress Syndrome; Tocilizumab; SARS-CoV-2; Monoclonal antibodies; Perú

A descriptive study was carried out, in which clinical and laboratory characteristics were evaluated in patients with a diagnosis of acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 infection and who received Tocilizumab. Twenty four patients received Tocilizumab, the majority were male (95.8%), the most frequent comorbidity was obesity (33.3%). At the time of receiving Tocilizumab the median PAO2 / FiO2 was 159.5 (IQR 114.5-255, 3). Twenty-one (87.5%) patients presented clinical improvement and 3 (12.5%) died. Fifteen patients (62.5%) developed hepatotoxicity, the majority grade 3 (33.3%) and three (12.5%) patients presented grade 4 liver injury. Eleven patients (45.8%) presented bacterial superinfection, the more common organism being Acinetobacter baumannii. After the administration of Tocilizumab, more than half of the patients presented an adverse reaction; despite this, mortality was low, and the majority had a clinical improvement.